Witte P U, Metzger H, Eckert H G, Irmisch R
Arzneimittelforschung. 1984;34(10B):1448-51.
In healthy volunteers a single oral dose of 5 mg 2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) was well tolerated. Following 5 mg Hoe 498 plasma angiotensin converting enzyme (ACE) activity was inhibited by almost 100% up to 8 h. A marked effect on plasma ACE was observed for more than 8 days. Plasma renin activity increased whereas aldosterone plasma levels decreased only slightly. Sodium and potassium excretion was not influenced by the compound. Systolic and diastolic blood pressure was slightly lowered by Hoe 498, whereas no relevant changes in pulse rate were observed.
在健康志愿者中，单次口服5毫克2-[N-[(S)-1-乙氧羰基-3-苯基丙基]-L-丙氨酰基]-(1S,3S,5S)-2-氮杂双环[3.3.0]辛烷-3-羧酸（Hoe 498）耐受性良好。服用5毫克Hoe 498后，血浆血管紧张素转换酶（ACE）活性在长达8小时内几乎被抑制100%。在超过8天的时间里观察到对血浆ACE有显著影响。血浆肾素活性增加，而醛固酮血浆水平仅略有下降。该化合物对钠和钾排泄没有影响。Hoe 498使收缩压和舒张压略有降低，而脉搏率未观察到相关变化。
